Because of the importance of TNFα in NAFLD and the distinct roles of the two TNFRs, therapeutic interventions should lead to NAFLD regression, but avoid side effects, such as infections, which are frequently observed with conventional TNFα antagonists. This evidence concerns the gene TNF and metabolic dysfunction-associated steatotic liver disease.